Intelligent Automation in Pharmacovigilance
pharmafile | November 27, 2017 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | biotech, drugs, pharma, pharmaceutical, pharmacovigilance, primevigilance
PrimeVigilance is pleased to announce their collaboration with the International Society of Pharmacovigilance (ISoP) on the upcoming seminar, organised by its CEO Dr Jan Petracek and hosted by Biogen.
The “Intelligent Automation in Pharmacovigilance” seminar offers a unique, highly focused and scientific exploration of emerging tools in process automation and the challenges their implementation brings to pharmacovigilance activities. The event will be held on December 4-5, 2017 in Cambridge (Boston), USA.
Event Overview:
The seminar will also answer questions on how automated processes powered by artificial intelligence could provide effective solutions to the ever-increasing challenges in pharmacovigilance. Where over 30 top international speakers from most influential companies in the area of pharmacovigilance automation will present the state of the art and examine the disruption coming to our industry.
This enables pharmacovigilance leaders to make better informed decisions, while being ready for innovation, that is already on its way to our industry.
The confirmed speakers and panellists include:
- Alexander Kluczka, Global Pharmacovigilance, Head of TA Oncology ICSR Processing, Bayer
- Diane Beck, Vice President, Head of Pharmacovigilance Services, Takeda
- Taxiarchis Botsis, Pharmacovigilance Project Manager, US FDA
- Sean Darcy, Senior Director, Pharmacovigilance, Alnylam
- Mark Fletcher, Executive Vice President, Automation Anywhere
- Tauqeer Karim, Vice President, Fresenius Medical Care
- Monica Mehta, Seasoned PV Operations Leader, Biogen
- Mark Mannion, Managing Director, Extra Technology
- Jan Petracek, CEO, PrimeVigilance
- Andrew Rut, CEO, MyMeds&Me
- Shui Ki Henry Seto, Vice President, Head of Global Patient Safety, Vertex Pharmaceuticals
- Priya Singhal, Senior Vice President, Global Head of Safety and Benefit-Risk Management, Biogen
- Sameer Thapar, Director, Global Head of Pharmacovigilance, Oracle
- Phil Tregunno, Signal Management Unit Manager, MHRA
- Wayne Jack Wallis, Executive Director and Pharmacovigilance Research Fellow, Celgene April Davis, Industry Principal Director, Accenture
At the end of the seminar, pharmacovigilance leaders should be able to make robust, informed decisions when working with potentially disruptive innovation.
Who should attend?
This seminar is aimed to engage all interested pharmacovigilance professionals in an industry, regulatory, or university setting. Training certificates of attendance will be provided to those who complete the seminar.
To view the programme click here
Registration and housing information can be found on the ISoP website.
Related Content
FDA approves IMIDEX’s AI-powered device VisiRad XR
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …
Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo
On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …
Zumutor’s cancer drug trial cleared by FDA
On 11 August 2023, the biopharmaceutical company Zumutor Biologics announced that the trial of its …
